Biotech Values

[xavierprivas]

The same three PARP drugs, CLVS Rubraca, JNJ (TSRO) Zejula and AZN Lynparza
battle for approval in prostate cancer.

I used to own CLVS in the similar battle for ovarian cancer years ago and
I sold it for a decent profit. I volunteer at this cancer support group
in Atlanta and years ago I notice that Lynparza and Zejula were marketed
heavily to this cancer support group for ovarian but no presence from CLVS.

Based on this anecdotal evidence I sold all CLVS back then and never looked
back. I have a feeling it would the same crummy marketing as before.
Back then CLVS could stand a chance as TSRO was a small company, it would
be difficult to compete with JNJ or AZN salesforce now. Just my opinion.